Bone Biologics (NASDAQ: BBLG) outlines 2025 milestones, 2026 plans

Rhea-AI Filing Summary

Bone Biologics Corporation filed a current report to furnish, rather than file, a press release dated January 8, 2026. The press release summarizes the company’s corporate, scientific and operational milestones achieved during 2025 and outlines its strategic outlook for 2026. This information is provided under Item 7.01 of the Exchange Act and is expressly not deemed filed or subject to Section 18 liabilities, nor incorporated by reference into other Securities Act or Exchange Act filings. The press release is included as Exhibit 99.1 to the report.

false 0001419554 0001419554 2026-01-08 2026-01-08 0001419554 BBLG:CommonStockParValue0.001PerShareMember 2026-01-08 2026-01-08 0001419554 BBLG:WarrantsToPurchaseCommonStockParValue0.001PerShareMember 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-40899		42-1743430
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2 Burlington Woods Drive, Ste. 100 Burlington, MA		01803
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 552-4452

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		BBLG		Nasdaq Capital Market
Warrants to Purchase Common Stock, par value $0.001 per share		BBLGW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 8, 2026, Bone Biologics Corporation (the “Company”) issued a press release summarizing the corporate, scientific and operational milestones achieved during 2025 and outlining its strategic outlook for 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 8, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BONE BIOLOGICS CORPORATION
Date: January 8, 2026
	By:	/s/ Jeffrey Frelick
		Jeffrey Frelick
		Chief Executive Officer

FAQ

What did Bone Biologics (BBLG) report in its latest 8-K filing?

Bone Biologics filed a current report to furnish a press release that summarizes its 2025 corporate, scientific and operational milestones and presents a strategic outlook for 2026.

What is the focus of Bone Biologics’ January 8, 2026 press release?

The press release highlights Bone Biologics’ 2025 corporate, scientific and operational milestones and outlines the company’s strategic plans and outlook for 2026.

Where can investors find the Bone Biologics 2025 milestones and 2026 outlook details?

The detailed information is contained in the press release furnished as Exhibit 99.1 to the current report.

Is the Bone Biologics press release considered filed for Exchange Act liability purposes?

No. The information furnished under Item 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other company filings.

On which exchange is Bone Biologics listed and what are its trading symbols?

Bone Biologics’ common stock trades on the Nasdaq Capital Market under the symbol BBLG, and its warrants trade under the symbol BBLGW.